許多公司正計劃推出 GLP-1 減肥藥,以挑戰市場領導者諾和諾德 (NVO) 和禮來 (LLY) 的主導地位。減肥藥大戰一觸即發。羅氏(RHHBY)、諾和諾德和一家規模較小的生物技術公司均在上周公布新數據,證實其口服藥物可能與注射劑一樣有效,但華爾街正在觀望,人們是否接受每天服用藥物,還是寧可每週或每月進行一次注射。
We recently published a list of Must-See: Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other Jim Cramer’s best stocks for investors. In a recent episode of Mad Money, Jim Cramer discussed how the slowing economy […]
GLP-1 pills are the next frontier for the weight-loss market.